Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Analysts
Aurinia Pharmaceuticals Inc (AUPH) has received a consensus "Hold" recommendation from analysts, with an average one-year target price of $17.25. The company recently surpassed Q4 earnings and revenue expectations, reporting an EPS of $1.53 against an estimated $0.21. Insider activity shows Director Kevin Tang acquiring a significant number of shares, increasing his stake by approximately 4.56%.
Aurinia to Acquire Kezar via $6.955-Per-Share Cash Tender Plus CVR
Aurinia Pharmaceuticals announced a definitive agreement to acquire Kezar Life Sciences for $6.955 per share in cash plus a contingent value right. The deal is expected to close in Q2 2026 and includes a CVR agreement for sharing future value from Kezar's cash and legacy assets. Tang Capital Partners has agreed to tender its 9% stake, increasing the likelihood of the deal's success.
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has announced its intent to acquire Kezar Life Sciences (NASDAQ: KZR) for $6.955 per share in cash plus one non-transferable contingent value right (CVR). The CVR offers potential additional payments tied to Kezar’s closing net cash, proceeds from existing agreements, and future development or monetization of its lead asset zetomipzomib and other legacy assets for up to 10 years. A key Kezar shareholder, Tang Capital Partners, LP, holding approximately 9.0% of the stock, has agreed to tender its shares, and the transaction is expected to close in Q2 2026.
How Aurinia Pharmaceuticals Inc (AUPH) Affects Rotational Strategy Timing
The article analyzes Aurinia Pharmaceuticals Inc (AUPH), indicating strong sentiment across all horizons supporting an overweight bias. It highlights a mid-channel oscillation pattern and an exceptional 37.4:1 risk-reward short setup. The analysis provides specific institutional trading strategies, including long, momentum breakout, and risk hedging, with detailed entry/target/stop-loss zones and multi-timeframe signal analysis for various holding periods.
Aurinia Pharmaceuticals (AUPH) CFO Michael Hearne becomes reporting insider with Form 3
Aurinia Pharmaceuticals Inc. announced that its Chief Financial Officer, Michael S. Hearne, has filed an initial Form 3, establishing his status as a reporting insider. This filing is a regulatory requirement for officers, directors, and large shareholders, indicating that Hearne will now be subject to future ownership and transaction reporting. The Form 3 itself does not disclose any specific shareholdings or recent trading activity by Mr. Hearne, serving primarily as an initial statement of beneficial ownership.
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline
Aurinia Pharmaceuticals announced a definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash, plus a contingent value right. This acquisition is set to expand Aurinia's autoimmune pipeline with Kezar's lead product candidate, zetomipzomib, an immunoproteasome inhibitor. The deal, unanimously approved by Kezar's board, is expected to close in the second quarter of 2026 and will provide immediate liquidity to Kezar shareholders while advancing the development of zetomipzomib.
EBIT per share of Aurinia Pharmaceuticals Inc. – LSE:0UJF
The article focuses on the EBIT per share for Aurinia Pharmaceuticals Inc. (LSE:0UJF). It is a financial data point presented within the context of TradingView's platform, indicating specific financial performance for the company.
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal
Aurinia Pharmaceuticals announced its agreement to acquire Kezar Life Sciences for $6.955 per share in cash plus a non-transferable contingent value right (CVR). This acquisition aims to expand Aurinia's portfolio in autoimmune disease treatments, particularly with Kezar's zetomipzomib. The deal, supported by Kezar's board and key investors, is expected to close in the second quarter of 2026.
Kezar Life Sciences stock jumps on Aurinia acquisition deal
Kezar Life Sciences Inc. (NASDAQ:KZR) shares surged 19.2% after Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its intent to acquire Kezar for $6.955 in cash per share plus a contingent value right. The acquisition, unanimously approved by Kezar's board, includes potential future payments tied to zetomipzomib's development and other collaborations. Aurinia plans to commence a tender offer by April 13, 2026, with the transaction expected to close in the second quarter of 2026.
Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is set to acquire Kezar Life Sciences, Inc. (NASDAQ: KZR) for $6.955 per share in cash plus one non-transferable contingent value right (CVR). The CVR offers potential additional cash tied to the development of zetomipzomib, proceeds from existing collaborations, and Kezar's net cash exceeding $50 million. Kezar's board has unanimously approved the merger, and a major stockholder, Tang Capital Partners, LP, has agreed to tender its 9.0% stake.
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Aurinia Pharmaceuticals announced its definitive merger agreement to acquire Kezar Life Sciences for $6.955 per share in cash, plus a contingent value right (CVR). The CVR includes potential payments related to Kezar's lead product candidate, zetomipzomib, collaborations, and net cash. This acquisition aims to enhance Aurinia's portfolio in autoimmune disease treatments, leveraging Kezar's immunoproteasome inhibitor.
How Aurinia’s Tang-Led C-Suite Overhaul Will Impact Aurinia Pharmaceuticals (AUPH) Investors
Aurinia Pharmaceuticals recently underwent a significant leadership change, with Kevin Tang moving from Board Chair to CEO, accompanied by a new C-suite. This overhaul aims to consolidate operational control and signals a potential shift in the company's strategy regarding capital allocation and pipeline priorities. Investors will be watching how this new leadership impacts the commercial performance of LUPKYNIS and the development of its early autoimmune pipeline, especially given the company's Q1 2026 revenue guidance.
AUPH Should I Buy
Intellectia AI™ recommends Aurinia Pharmaceuticals Inc (AUPH) as a good long-term buy for beginner investors, citing strong financial growth in Q4 2025, positive corporate governance changes, and shareholder-focused initiatives. Despite a slight drop in gross margin and lack of recent insider trading, technical analysis indicates bullish momentum. Wall Street analysts have a "Moderate Buy" consensus, with average price targets suggesting an increase, though one analyst downgraded due to concerns about product reach and competitive landscape.
AURINIA PHARMACEUTICALS PB Ratio: 3.29 — 11% Below Median
Aurinia Pharmaceuticals Inc. (AUPH) currently has a PB Ratio of 3.24 as of March 27, 2026, which is 13% below its 10-year median. The stock is considered "Fairly Valued" by GuruFocus, trading 7.9% above its estimated fair value of $13.18, and has a GF Score™ of 85/100 with three warning signs. AUPH's PB Ratio places it worse than 55.16% of biotechnology companies, being 12.9% above the industry median of 2.87.
[SCHEDULE 13D/A] Aurinia Pharmaceuticals Inc. Amended Major Shareholder Report
Tang Capital Management and its affiliated funds have disclosed an amended beneficial ownership of 12,229,500 common shares in Aurinia Pharmaceuticals Inc., representing 9.2% of the class. The amendment also highlights that Kevin Tang was appointed Chief Executive Officer of Aurinia Pharmaceuticals on March 23, 2026. This significant shareholder position combined with the CEO role aligns management and shareholder interests.
Aurinia Resets Leadership And Capital Plans As Valuation Gap Persists
Aurinia Pharmaceuticals has undergone a major leadership reshuffle, appointing a new CEO, COO, CFO, and CSO, and reducing its board size. The company plans to discontinue non-core R&D programs, introduce performance-based incentives, and execute a substantial share repurchase plan. This strategic overhaul aims to address the valuation gap and improve capital allocation, as the stock trades significantly below its estimated fair value despite a positive long-term return.
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up
Aurinia Pharmaceuticals (AUPH) experienced a stock rally following a complete overhaul of its C-suite, which included the appointment of hedge fund manager Kevin Tang as the new CEO. This leadership change comes after Peter Greenleaf's seven-year tenure and has fueled speculation about a potential acquisition for the biotech company.
Aurinia appoints Kevin Tang as CEO with zero compensation
Aurinia Pharmaceuticals Inc. has appointed Kevin Tang as its new CEO, effective immediately, with zero compensation in salary, bonuses, or equity awards. This appointment follows the departure of former CEO Peter Greenleaf and his team, and is a result of a multi-year campaign for governance reforms by significant shareholder MKT Capital Ltd. The company has also reported strong financial results for Q4 2025 with earnings and revenue exceeding expectations, along with other recent corporate changes including a share repurchase program and board reduction.
Aurinia Reshapes Executive Team as Board Chair Kevin Tang Becomes CEO
Aurinia Pharmaceuticals (AUPH) has announced significant leadership changes, with Board Chair Kevin Tang taking over as CEO, succeeding Peter Greenleaf. The company also expanded its executive team by appointing a new COO, CFO, and CSO to bolster its operational and scientific capabilities. These changes aim to leverage the success of LUPKYNIS and advance Aurinia's autoimmune pipeline, reinforcing its position in the market.
Aurinia Pharmaceuticals Inc. Appoints Michael Hearne as Chief Financial Officer
Aurinia Pharmaceuticals Inc. has announced the appointment of Michael Hearne as its new Chief Financial Officer. This news comes amidst other executive leadership changes within the company. Aurinia Pharmaceuticals is a biopharmaceutical company specializing in autoimmune diseases, known for its therapy LUPKYNIS.
Aurinia appoints Kevin Tang as CEO and Ryan Cole as COO
Aurinia has announced significant changes to its executive leadership, appointing Kevin Tang as Chief Executive Officer, Ryan Cole as Chief Operating Officer, and Michael Hearne as Chief Financial Officer, all effective March 23, 2026. These appointments follow the cessation of several prior officers' service and a new Lead Independent Director being named. The new leadership team brings extensive experience from Tang Capital Management and other pharmaceutical companies.
Aurinia Announces Management Transition
Aurinia Pharmaceuticals Inc. announced a management transition, with Kevin Tang succeeding Peter Greenleaf as CEO. The company also appointed Ryan Cole as COO, Michael Hearne as CFO, and Thomas Wei as CSO, while Stew Kroll and Stephen Robertson will continue in their current roles. Aurinia thanked Peter Greenleaf for his contributions and highlighted the strong position of LUPKYNIS and the advancement of its pipeline product, aritinercept.
Aurinia (NASDAQ: AUPH) installs Kevin Tang as CEO amid broad C-suite exits
Aurinia Pharmaceuticals Inc. has announced a significant leadership overhaul, appointing Kevin Tang as the new CEO, who will receive no compensation for his role. The company also named Ryan Cole as COO and Michael Hearne as CFO, both with substantial salaries and equity options. This transition follows the departure of the previous CEO, COO, CMO, and CFO, with Peter Greenleaf, the former CEO, remaining as a consultant for a three-month period to ensure a smooth transition.
MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition
MKT Capital, a significant shareholder in Aurinia Pharmaceuticals, has applauded the company's decision to remove CEO Peter Greenleaf and appoint Kevin Tang as the new CEO. MKT Capital sees this as a validation of its multi-year shareholder campaign for accountability and disciplined capital allocation, particularly noting Tang's commitment to zero CEO compensation. The firm believes these changes will usher in a new era of value creation for Aurinia shareholders.
Aurinia Pharmaceuticals Stock Rises 6% Over Leadership Transition
Aurinia Pharmaceuticals Inc. (AUPH) shares rose 6% following the announcement of a leadership transition. Kevin Tang, the current Board Chair, will succeed Peter Greenleaf as CEO. Additionally, the company appointed Ryan Cole as COO, Michael Hearne as CFO, and Thomas Wei as Chief Scientific Officer.
AUPH SEC Filings - Aurinia Pharmace 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Aurinia Pharmaceuticals Inc. (AUPH) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing financial results, share repurchase plans, and clinical developments, along with AI-powered summaries to help investors quickly analyze key information. The page also includes recent insider buying activity by Director Kevin Tang and current stock data for AUPH.
AUPH SEC Filings - Aurinia Pharmace 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Aurinia Pharmaceuticals Inc.'s (NASDAQ: AUPH) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights how these documents, complemented by AI-powered summaries, offer insights into the company's financial performance, clinical developments, and insider transactions. Recent filings detail insider share withholdings for tax purposes and the company's Q3 2025 financial results, showing increased profit and revenue driven by LUPKYNIS sales.
Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration
Aurinia Pharmaceuticals has increased its 2025 revenue forecast for its kidney disease drug, LUPKYNIS, to $270 million, up from previous projections. The company highlights strong market penetration and accelerated demand for the drug, indicating confidence in its continued growth and impact on the lupus nephritis treatment landscape.
Aurinia Pharmaceuticals (AUPH) stock drops after strong quarter, softer forward revenue targets
Aurinia Pharmaceuticals (AUPH) experienced a stock drop despite reporting a strong first quarter, which included record net product revenue for its drug Lupkynis. The decline followed the company's Q2 revenue guidance falling below analyst expectations, even as it maintains its full-year 2024 revenue forecast.
Aurinia (AUPH) SVP has 8,069 shares withheld for taxes
Aurinia Pharmaceuticals Inc.'s SVP and Chief Medical Officer, Greg Keenan, had 8,069 common shares withheld on March 6, 2026, to cover tax obligations related to vested restricted stock units. This transaction, valued at $14.32 per share, is described as a routine tax withholding and not a discretionary sale. Keenan still retains a significant stake in the company, holding 154,449 common shares after this administrative event.
Responsive Playbooks and the AUPH Inflection
This article analyzes Aurinia Pharmaceuticals Inc (AUPH) using AI models to provide trading strategies. It identifies weak near-term sentiment but potential long-term strength, offering position, momentum breakout, and risk hedging strategies based on multi-timeframe signal analysis. The report highlights support and resistance levels across different time horizons for investors.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts
Analysts have issued a consensus "Hold" rating for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), with an average 12-month price target of $17.25. The company recently exceeded quarterly earnings expectations, reporting an EPS of $1.53 against an estimated $0.21, and revenue of $77.11 million surpassing the $74.7 million estimate. Additionally, a significant insider purchase was reported, with Director Kevin Tang acquiring over 500,000 shares, increasing his stake in the company.
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Growth And Optimistic 2026 Guidance
Aurinia Pharmaceuticals (AUPH) recently released strong 2025 earnings and optimistic 2026 guidance, projecting $315 million to $325 million in total revenue. Despite a 78.53% one-year total shareholder return, the stock is currently estimated to be 12.9% undervalued, with a fair value of $17.00 against its current price of $14.80. The valuation considers the company's autoimmune franchise but acknowledges risks such as potential competition for LUPKYNIS and drug pricing pressures.
Aurinia Pharma’s Wild Ride: What AUR’s Lupus Bet Means For You
Aurinia Pharmaceuticals (AUR) is gaining attention for Lupkynis, its FDA-approved drug for lupus nephritis, a serious kidney complication. The company is evaluating sales growth, insurance coverage, and pipeline studies while investors debate its potential as a long-term winner or a takeover target. The article highlights the drug's impact on US patients and the financial considerations involved for both patients and investors, emphasizing the high-risk, high-upside nature of this autoimmune play.
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 50-Day Moving Average - Should You Sell?
Aurinia Pharmaceuticals (NASDAQ:AUPH) stock recently fell below its 50-day moving average, trading as low as $14.41 before closing at $14.80. Despite beating earnings estimates with significant EPS and revenue, analysts maintain a consensus "Hold" rating with an average price target of $17.25. Insider Kevin Tang also increased his stake, purchasing over 500,000 shares in February.
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Growth And Optimistic 2026 Guidance
Aurinia Pharmaceuticals (AUPH) recently released strong 2025 earnings and optimistic 2026 guidance, projecting total revenue of US$315 million to US$325 million. Despite some short-term cooling in share price momentum, the company's one-year total shareholder return is 78.53%. Simply Wall St estimates Aurinia's fair value at $17.00, suggesting it is currently undervalued by 12.9% at a share price of US$14.80.
The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following Strong 2025 Results And Upbeat 2026 Outlook
Aurinia Pharmaceuticals reported strong fourth-quarter and full-year 2025 results, with significant increases in revenue, net income, and earnings per share. The company also issued an optimistic 2026 guidance, projecting double-digit revenue growth driven by continued uptake of its drug LUPKYNIS. These positive developments may significantly alter the investment narrative for AUPH, although the risk of single-drug dependency remains a key concern.
Tang Capital boosts Aurinia (AUPH) stake to 9.2% ownership
Tang Capital Management and its affiliates have increased their beneficial ownership in Aurinia Pharmaceuticals Inc. (AUPH) to 9.2% of the outstanding common shares, totaling 12,229,500 shares as of February 25, 2026. The reporting group spent approximately $26.3 million to purchase an additional 2,200,000 shares through open-market transactions since March 4, 2025. This significant stake gives Tang Capital influence over the company, with shared voting and dispositive power among the involved entities and Kevin Tang.
Aurinia (NASDAQ: AUPH) CFO gets stock, options; covers tax bill
Aurinia Pharmaceuticals Inc. CFO Joseph M. Miller received 95,700 employee stock options and 57,229 shares of common stock on February 27, 2026. The stock options have a zero exercise price and a vesting schedule, while performance rights are tied to stock price targets. Additionally, 37,511 common shares were withheld to cover tax obligations related to the vesting of restricted stock units, leaving Miller with 576,421 directly held common shares.
Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings
Aurinia Pharmaceuticals (AUPH) has experienced recent share price volatility, with its stock currently around US$14.21. Despite short-term fluctuations, the company has shown strong 1-year and 3-year total shareholder returns. Simply Wall St's analysis suggests AUPH is undervalued, with a fair value of $16.67, driven by steady top-line expansion, firmer margins, and a lower earnings multiple, though risks related to its main product, LUPKYNIS, and R&D spending could impact this assessment.
Aurinia (AUPH) CMO awarded new stock options and share grant
Aurinia Pharmaceuticals Inc. (AUPH) Chief Medical Officer, Greg Keenan, was granted new equity awards on February 27, 2026. These awards include stock options for 67,870 shares and common stock for 40,586 shares, both at an exercise/stated price of $0, increasing his total holdings. The footnotes explain the vesting schedules for these awards, which are based on share price targets and time-based conditions.
Aurinia (AUPH) COO receives stock grants and settles taxes with shares
Aurinia Pharmaceuticals Inc.'s Chief Operating Officer, Matthew Maxwell Donley, received grants of 97,256 employee stock options and 58,160 shares of common stock. Subsequently, 40,761 common shares were disposed of to cover tax obligations upon the vesting of restricted stock units. After these transactions, Donley directly holds 680,299 common shares in the company.
Tang Capital LPs tied to Aurinia (NASDAQ: AUPH) buy 900K shares
Entities associated with Aurinia Pharmaceuticals Inc. director Kevin Tang reported significant open-market purchases of 900,000 common shares between February 27 and March 3, 2026. These transactions, executed by various limited partnerships at weighted-average prices in the mid-to-high teens per share, increased Tang-associated entities' beneficial ownership to over 12 million Aurinia common shares. The Form 4 filing details the individual transactions and the indirect nature of the ownership.
Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock
Aurinia Pharmaceuticals director Kevin Tang recently purchased 516,439 shares of AUPH stock worth over $7.2 million, increasing his direct stake to 11.8 million shares. The company surpassed quarterly earnings and revenue expectations, reporting $1.53 EPS against an estimated $0.21 and $77.11 million in revenue. Despite a "Hold" consensus rating from analysts with an average price target of $17.25, the stock trades near $14.15 with a market capitalization of $1.88 billion.
Aurinia Pharmaceuticals Inc (AUPH): Investor Outlook Reveals 19.63% Potential Upside
Aurinia Pharmaceuticals Inc (AUPH) is attracting investor attention with a potential upside of 19.63%. The biotechnology company, specializing in autoimmune diseases with its product LUPKYNIS, has a market capitalization of $1.87 billion and a forward P/E ratio of 17.02, alongside impressive revenue growth of 28.80%. Analyst sentiment is largely favorable, with an average target price of $17.00, suggesting significant growth potential.
Aurinia (AUPH) EVP gets stock awards and has shares withheld for taxes
Aurinia Pharmaceuticals Inc.'s EVP and General Counsel, Stephen P. Robertson, reported receiving a grant of 98,813 employee stock options and 59,090 common shares on February 27, 2026. On March 2, 2026, 36,525 common shares were disposed of at $14.21 per share to cover tax withholding obligations upon the vesting of restricted stock units. Following these transactions, Robertson directly owns 505,861 common shares in the company.
GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH
GSA Capital Partners LLP significantly reduced its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 95.9% in Q3, selling over 267,000 shares. Despite this, other institutions like Hussman Strategic Advisors and Schroder Investment Management Group increased their holdings, and new positions were opened by Ritholtz, Marex, and Navellier, with institutions now owning 36.83% of the company. Aurinia Pharmaceuticals reported strong Q3 earnings, beating EPS and revenue expectations, and its stock is currently trading around $14.21 with a market cap of $1.89 billion.
Aurinia Pharmaceuticals (AUPH) Earnings Spike Above Revenue Challenges Profit Quality Narratives
Aurinia Pharmaceuticals (AUPH) reported strong FY 2025 results with Q4 revenue of US$77.1 million and EPS of US$1.60, with trailing twelve-month net income slightly exceeding revenue. While bulls highlight stronger LUPKYNIS adoption and cost discipline, the significant portion of non-cash earnings and analyst forecasts for future declines raise questions about the sustainability and quality of these profits. Investors are encouraged to analyze the data to form their own conclusions given the conflicting narratives.
Aurinia’s LUPKYNIS Strength And Aritinercept Progress Versus Valuation Signals
Aurinia Pharmaceuticals reported strong LUPKYNIS sales and a tax benefit, boosting net income, while also advancing a new clinical study for aritinercept. Despite this progress, including the termination of a pediatric VOCAL study, the stock has shown short-term weakness, trading below analyst targets but flagged as undervalued by Simply Wall St. Key considerations for investors include monitoring aritinercept trial progress and the company's P/E ratio, along with flagged risks like high non-cash earnings.
Aurinia’s LUPKYNIS Strength And Aritinercept Progress Versus Valuation Signals
Aurinia Pharmaceuticals reported strong commercial performance of LUPKYNIS, which, combined with a tax benefit, boosted its net income. The company is advancing a new clinical study for aritinercept in autoimmune diseases but terminated a pediatric VOCAL study, leading to ongoing discussions with regulators. Despite recent stock declines, analysts view the shares as undervalued, trading about 17% below the target price and a much lower P/E ratio compared to the biotech industry average.
